98%
921
2 minutes
20
Background: Preoperative diagnosis of parathyroid cancer (PC) where possible allows for en-bloc resection of the tumour, which is associated with excellent prognosis. The rule of >3 (size of tumour larger than 3 cm; corrected calcium more than 3 mmol/L) as proposed by Schulte and Talat has a specificity of 95% in predicting malignancy in parathyroid neoplasms. We looked at the impact of rule of 3 in predicting malignancy and outcomes on intervention in a South Asian cohort.
Methods: Patients who underwent parathyroid surgery between 2010 and 2023 at two tertiary referral centres were assessed. Patients with PC were selected and their clinicopathological parameters, treatment modalities, and outcomes were analysed.
Results: Thirteen of 336 (3.8%) patients with a mean age of 61.8 (±17.5) years were diagnosed with PC during the study period. The highest mean preoperative values were PTH (92.4 ± 66.27 pmol/L), highest corrected calcium (3.21 ± 0.28 mmol/L), and alkaline phosphatase (419 IU/mL). Nine patients underwent en-bloc excision while the other had focussed parathyroidectomy. Recurrences were recorded in 2 (28.5%) patients over a mean follow-up period of 69 (±48.6) months. One patient with lung metastasis underwent video-assisted thoracic surgery. There was no disease specific mortality in this cohort during the study period.
Conclusions: In our experience, the predictive rule of 3 has low sensitivity to suspect PC preoperatively, resulting in limited usefulness in clinical practice. Outcomes appear to be less favourable with higher recurrence rates in cases where less than en-bloc resection is performed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048100 | PMC |
http://dx.doi.org/10.1159/000541543 | DOI Listing |
Ann Med
December 2025
Department of Thyroid Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, P.R. China.
Medicine (Baltimore)
September 2025
Department of Internal Medicine, Lahore General Hospital, Lahore, Punjab, Pakistan.
Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).
Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.
Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.
Endocr Relat Cancer
September 2025
Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
Bone metastases (BMs) are rare and late event in patients with neuroendocrine tumors (NETs). The aim of our study was to investigate clinical presentation and outcome of BMs in a large cohort of patients with NETs. A retrospective study was performed at two referral centers of Northern Italy (IRCCS Humanitas Research Hospital in Milan and S.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
University of Michigan, Ann Arbor, MI, USA.
Background: Hypocalcemia is common after cervical procedures. Patients who have undergone Roux-en-Y gastric bypass (RYGB) experience increased risk for post-thyroidectomy hypocalcemia. This association has not been elucidated for nonbariatric operations that bypass the duodenum.
View Article and Find Full Text PDFTher Adv Endocrinol Metab
September 2025
Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th Street, New York, NY 10021, USA.
Cancer negatively impacts bone health through various mechanisms, including treatment-induced bone loss and malignant bone lesions, often leading to increased fracture risk and higher morbidity and mortality. Antiresorptive agents (bisphosphonates and denosumab) are the current standard of care to reduce the risk of skeletal-related events and prevent treatment-related fragility fractures in patients with cancer. While there is strong evidence to support their benefits in cancer, there is potential room for further reduction in the risk of pathologic and fragility fractures.
View Article and Find Full Text PDF